Therefore, the combined treatment with anti-EGFR drugs, such as cetuximab, and with specific inhibitors for IGF2BP3 or m6A, can be a potential therapeutic strategy to investigate in a clinical setting for overcoming intrinsic or acquired resistance to EGFR inhibitors in patients with CRC. Here, IGF2BP3 is linked to colorectal carcinoma.